Journal of cardiology最新文献

{"title":"Impact of diabetes mellitus on post-CABG outcomes in veterans: Insights from the REGROUP trial","authors":"Thais Faggion Vinholo MD, MSc , Eileen Stock PhD , Jordan Bloom MD, MPH , Sameer Hirji MD, MPH , Ellen DeMatt MA , Kousick Biswas PhD , Jacquelyn A. Quin MD, MPH , Miguel Haime MD , Marco A. Zenati MD","doi":"10.1016/j.jjcc.2024.09.007","DOIUrl":"10.1016/j.jjcc.2024.09.007","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 418-420"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-specific differences of Impella support in Japanese patients: The Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) registry analysis on outcomes and adverse events","authors":"Akihiro Shirakabe MD, PhD ,&nbsp;Masato Matsushita MD, PhD ,&nbsp;Shota Shigihara MD ,&nbsp;Suguru Nishigoori MD ,&nbsp;Tomofumi Sawatani MD ,&nbsp;Kenichi Tani MD ,&nbsp;Masaki Morooka MD ,&nbsp;Kuniya Asai MD, PhD ,&nbsp;J-PVAD Investigators","doi":"10.1016/j.jjcc.2024.11.007","DOIUrl":"10.1016/j.jjcc.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>The association between the clinical significance and prognostic impact of catheter-based micro-axial ventricular assist device Impella (Abiomed, Danvers, MA, USA) support and age has not been sufficiently investigated.</div></div><div><h3>Methods and results</h3><div>A total of 5282 patients treated with Impella were analyzed from the Japanese registry for Percutaneous Ventricular Assist Device (J-PVAD). Patients were categorized into four age groups: &lt;50 years old (Group A, <em>n</em> = 670), 50–69 years old (Group B, <em>n</em> = 2009), 70–79 years old (Group C, <em>n</em> = 1716), and ≥80 years old (Group D, <em>n</em> = 887). Kaplan–Meier curve analysis demonstrated that the prognosis, including 30-day all-cause mortality, was significantly poorer in Group D compared to the other groups. A multivariate Cox regression model identified Group D as an independent predictor of 30-day all-cause death (HR: 2.173, 95 % CI: 1.699–2.779) relative to Group A. The multivariate logistic regression analysis indicated that estimated glomerular filtration rate, lactate levels, and systolic blood pressure were independently associated with 30-day mortality across all age categories. The presence of more than two major adverse events was independently associated with 30-day mortality specifically in the cohort aged ≥80 years (OR: 1.492, 95 % CI: 1.037–2.148, <em>p</em> = 0.031).</div></div><div><h3>Conclusion</h3><div>Increasing age was identified as a significant factor associated with higher 30-day mortality rates in J-PVAD. While the incidence of major adverse events did not differ significantly across age categories, the occurrence of two or more additional adverse events was linked to increased 30-day mortality among older individuals. Therefore, an appropriate mechanical support strategy may be necessary for elderly Japanese patients based on their age.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 343-351"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ECPELLA support on 1-year outcomes and myocardial damage in patients with acute myocardial infarction and refractory cardiogenic shock: A single-center retrospective observational study","authors":"Takashi Unoki MD ,&nbsp;Tomoko Nakayama MD ,&nbsp;Keita Saku MD, PhD ,&nbsp;Hiroki Matsushita MD ,&nbsp;Taiji Inamori MD ,&nbsp;Junya Matsuura MD ,&nbsp;Takaaki Toyofuku MD ,&nbsp;Tomohide Sato MD ,&nbsp;Yutaka Konami MD ,&nbsp;Hiroto Suzuyama MD ,&nbsp;Masayuki Inoue MD ,&nbsp;Eiji Horio MD, PhD ,&nbsp;Kazuhisa Kodama MD, PhD ,&nbsp;Eiji Taguchi MD ,&nbsp;Takuya Nishikawa MD, PhD ,&nbsp;Tadashi Sawamura MD ,&nbsp;Koichi Nakao MD, PhD, FJCC ,&nbsp;Tomohiro Sakamoto MD, PhD, FJCC ,&nbsp;Ken Okumura MD, PhD ,&nbsp;Junjiro Koyama MD, PhD","doi":"10.1016/j.jjcc.2024.12.003","DOIUrl":"10.1016/j.jjcc.2024.12.003","url":null,"abstract":"<div><h3>Background</h3><div>Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) is a vital mechanical circulatory support for treating patients with refractory cardiogenic shock (CS). VA-ECMO can improve end-organ perfusion; however, it increases left ventricular (LV) afterload, resulting in further myocardial damage. ECPELLA, a combination of VA-ECMO and Impella (Abiomed Inc., Danvers, MA, USA) treatments, is an emerging modality to optimize end-organ perfusion and LV unloading. The impact of ECPELLA in refractory CS has not been established. We aimed to investigate the effects of ECPELLA on acute-phase LV damage and outcomes in patients with acute myocardial infarction (AMI) and refractory CS and compare them with those of VA-ECMO with an intra-aortic balloon pump (IABP).</div></div><div><h3>Methods</h3><div>This single-center retrospective observational study included 90 consecutive patients with AMI and refractory CS who received VA-ECMO between January 2012 and December 2022. Of these, 44 and 46 received ECPELLA and VA-ECMO with IABP, respectively. We assessed the serum creatine kinase myocardial band (CK-MB) levels and 1-year mortality.</div></div><div><h3>Results</h3><div>No significant differences were observed in the baseline characteristics and time from onset to reperfusion between the two groups. Compared with VA-ECMO with IABP, ECPELLA produced lower peak CK-MB levels (265 IU/L vs. 500 IU/L, <em>p</em> = 0.016) and a smaller area under the curve of CK-MB during the first 3 days (274 IU/L × d vs. 534 IU/L × d, <em>p</em> = 0.025). ECPELLA was associated with significantly lower 1-year mortality (64% vs 91%; <em>p</em> = 0.001). Cox proportional hazards analysis revealed that ECPELLA was inversely and independently associated with 1-year mortality (hazard ratio: 0.38, 95% confidence interval: 0.23–0.64; <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Our findings suggest that ECPELLA may offer myocardial protection and be associated with improved 1-year mortality in patients with AMI and refractory CS. Further prospective studies are needed to confirm these observations and better understand the potential benefits of ECPELLA in this population.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 352-359"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and short-term outcomes in patients with cardiogenic shock undergoing mechanical circulatory support escalation from intra-aortic balloon pump to impella: From the J-PVAD registry","authors":"Masashi Yokoi MD, PhD,&nbsp;Tsuyoshi Ito MD, PhD,&nbsp;Yasuhiro Shintani MD, PhD,&nbsp;Yu Kawada MD, PhD,&nbsp;Tatsuya Mizoguchi MD, PhD,&nbsp;Sayuri Yamabe MD, PhD,&nbsp;Kento Mori MD, PhD,&nbsp;Shohei Kikuchi MD, PhD,&nbsp;Shuichi Kitada MD, PhD,&nbsp;Toshihiko Goto MD, PhD,&nbsp;Yoshihiro Seo MD, PhD, FJCC,&nbsp;J-PVAD Investigators","doi":"10.1016/j.jjcc.2024.09.009","DOIUrl":"10.1016/j.jjcc.2024.09.009","url":null,"abstract":"<div><h3>Background</h3><div>An escalation strategy from intra-aortic balloon pump (IABP) to Impella (AbioMed, Danvers, MA, USA) is proposed in patients with cardiogenic shock (CS) refractory to IABP therapy, but its clinical data are lacking. This study aimed to elucidate the clinical characteristics and short-term outcomes in patients undergoing IABP-Impella escalation.</div></div><div><h3>Methods and results</h3><div>From the Japanese nationwide registry of Impella (J-PVAD), a total of 2578 patients with CS receiving Impella support were classified into the IABP-Impella group (n = 189) or the Primary Impella group (n = 2389). We applied 1:3 propensity score (PS) matching, selecting 185 patients and 555 patients, respectively. Before matching, the IABP-Impella group presented longer shock-to-Impella time, worse laboratory data, and more frequent inotropes and pulmonary artery catheter use than the Primary Impella group. After matching, the baseline characteristics were well-balanced. Regarding the 30-day clinical outcomes in the PS-matched cohort, there were no significant differences in the rates of mortality and major complications (a composite of bleeding, hemolysis, infection, stroke, myocardial infarction, limb ischemia, and vascular injury) between the groups. However, The IABP-Impella group showed a significantly higher rate of infection (10.3 % vs. 5.6 %, <em>p</em> = 0.042) and additional mechanical circulatory support use (34.1 % vs. 23.8 %, <em>p</em> = 0.008) than the Primary Impella group.</div></div><div><h3>Conclusions</h3><div>Compared to patients with primary Impella support, those undergoing IABP-Impella escalation showed similar 30-day mortality and major complications despite poorer clinical conditions before Impella support and a more complicated clinical course after Impella insertion.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 337-342"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemonitoring in heart failure care: Does feasibility equate to clinical benefit?","authors":"Hamrish Kumar Rajakumar MBBS","doi":"10.1016/j.jjcc.2024.11.006","DOIUrl":"10.1016/j.jjcc.2024.11.006","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 428-429"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging of cardiovascular disease: Current status and future perspective","authors":"Takehiro Nakahara MD, PhD ,&nbsp;Shinichiro Fujimoto MD, PhD, FJCC ,&nbsp;Masahiro Jinzaki MD, PhD, FJCC","doi":"10.1016/j.jjcc.2025.01.017","DOIUrl":"10.1016/j.jjcc.2025.01.017","url":null,"abstract":"<div><div>Advancements in knowledge of cardiovascular disease, pharmacology, and chemistry have led to the development of newer radiopharmaceuticals and targets for new and more suitable molecules. Molecular imaging encompasses multiple imaging techniques for identifying the characteristics of key components involved in disease. Despite its limitations in spatial resolution, the affinity for key molecules compensates for disadvantages in diagnosing diseases and elucidating their pathophysiology. This review introduce established molecular tracers involved in clinical practice and emerging tracers already applied in clinical studies, classifying the key component in A: artery, specifically those vulnerable plaque (A-I) inflammatory cells [¹⁸F-FDG]; A-II) lipid/fatty acid; A-III) hypoxia; A-IV) angiogenesis; A-V) protease [¹⁸F/⁶⁸Ga-FAPI]; A-VI) thrombus/hemorrhage; A-VII) apoptosis and A-VIII) microcalcification [¹⁸F-NaF]) and B: myocardium, including myocardial ischemia, infarction and myocardiopathy (B-I) myocardial ischemia; B-II) myocardial infarction (myocardial damage and fibrosis); B-III) myocarditis and endocarditis; B-IV) sarcoidosis; B-V) amyloidosis; B-VI) metabolism; B-VII) innervation imaging). In addition to cardiovascular-specific tracers tested in animal models, many radiotracers may have been developed in other areas, such as oncology imaging or neuroimaging. While this review does not cover all available tracers, some of them hold potential for future use assessing cardiovascular disease. Advances in molecular biology, pharmaceuticals, and imaging sciences will facilitate the identification of precise disease mechanisms, enabling precise diagnoses, better assessment of disease status, and enhanced therapeutic evaluation in this multi-modality era.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 386-398"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of adipose tissue depots with cardiac resynchronization therapy response and clinical outcomes: A CRT-HF Clinic substudy","authors":"Maximilian C. Volk DO ,&nbsp;Saeid Mirzai DO ,&nbsp;Ian Persits DO ,&nbsp;Kunaal S. Sarnaik BS ,&nbsp;Laurie Ann Moennich MS ,&nbsp;Po-Hao Chen MD, MBA ,&nbsp;John Rickard MD, MPH ,&nbsp;W.H. Wilson Tang MD","doi":"10.1016/j.jjcc.2024.09.011","DOIUrl":"10.1016/j.jjcc.2024.09.011","url":null,"abstract":"<div><h3>Background</h3><div>The region of adipose deposition is an important determinant in the outcomes of patients with heart failure (HF). However, the impact of regional adiposity on HF patients undergoing cardiac resynchronization therapy (CRT) remains unclear.</div></div><div><h3>Methods</h3><div>A retrospective cohort analysis was conducted on 95 patients from a single-center study, assessing post-CRT outcomes. Multi-slice body composition measurements of chest computed tomography before CRT placement were used for adipose quantification. Patients were stratified based on subcutaneous adiposity, intramuscular adiposity, and hepatic steatosis.</div></div><div><h3>Results/Conclusion</h3><div>Subcutaneous adiposity correlated with higher CRT response rates (44.4 % in subcutaneous adiposity vs 16.7 % in subcutaneous adipopenia, <em>p</em> = 0.009), while intramuscular adiposity was associated with increased pre-frailty (adjusted OR 14.17, 95 % CI 2.24–89.57, <em>p</em> = 0.005). The higher response to CRT in patients with subcutaneous adiposity may be secondary to preferred subcutaneous over ectopic adipose fat deposition, which is potentially protective against cardiomyocyte dysfunction. Thus, intramuscular adiposity could potentially serve as a prognostic tool for frailty in HF patients.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 421-423"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right ventricular longitudinal strain in valvular heart disease: A comprehensive review","authors":"Mana Ogawa MD, PhD,&nbsp;Asahiro Ito MD, PhD,&nbsp;Daiju Fukuda MD, PhD","doi":"10.1016/j.jjcc.2024.12.004","DOIUrl":"10.1016/j.jjcc.2024.12.004","url":null,"abstract":"<div><div>Right ventricular (RV) longitudinal strain has emerged as a crucial tool for evaluating RV systolic function in patients with heart disease. The complex anatomy of the RV presents challenges for functional assessment, traditionally conducted using conventional parameters, such as tricuspid annular plane systolic excursion and RV fractional area change. While these conventional methods are simple and practical, they have limitations in reflecting the majority of global RV systolic function. In contrast, RV longitudinal strain, measured using speckle tracking echocardiography, offers a more accurate evaluation of RV systolic function with high reproducibility. It is less dependent on angle and load and utilizes automated techniques. The utility of RV longitudinal strain in patients with valvular heart disease has been reported, showing its effectiveness in detecting early RV systolic dysfunction and providing valuable prognostic information compared to conventional methods. Treatment options for valvular heart disease include not only traditional open-heart surgery but also catheter-based interventions, which have become increasingly available in recent years. In addition to conventional risk assessment, considering treatment choices based on RV systolic function may be beneficial. This approach could provide a new method for determining the optimal treatment plan for individual patients. Despite challenges such as imaging quality and vendor-specific variability, RV longitudinal strain remains a valuable tool for early detection of RV systolic dysfunction, optimizing patient management, and improving outcomes. This review examines the clinical utility of RV longitudinal strain in patients with valvular heart disease, focusing on its prognostic value and role in patient management.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 366-373"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply.","authors":"Toshiaki Isogai, Kojiro Morita, Akira Okada, Hideo Yasunaga","doi":"10.1016/j.jjcc.2025.04.011","DOIUrl":"https://doi.org/10.1016/j.jjcc.2025.04.011","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital therapeutics in Japan: Present and future directions","authors":"Akihiro Nomura MD, PhD","doi":"10.1016/j.jjcc.2024.11.005","DOIUrl":"10.1016/j.jjcc.2024.11.005","url":null,"abstract":"<div><div>Digital therapeutics (DTx) represent an innovative approach to healthcare, leveraging software applications (apps) delivered through digital devices to treat medical conditions. This review focuses on three DTx apps approved in Japan, targeting nicotine dependence, hypertension, and insomnia. CureApp SC, the DTx system for nicotine dependence, comprises a patient smartphone app, an Internet of Things device for exhaled carbon monoxide measurement, and a Web-based physician app. A clinical trial demonstrated significantly higher rates of continuous abstinence in the intervention group than in the controls (63.9 % vs. 50.5 %, <em>p</em> = 0.001) at 24 weeks, with effects persisting through 52 weeks. For hypertension management, CureApp HT focuses on lifestyle modifications with daily home blood pressure monitoring. The HERB-DH1 trial showed a significant reduction in 24-h systolic blood pressure (between-group difference, −2.4 mmHg; <em>p</em> = 0.024) and morning home blood pressure (between-group difference, −4.3 mmHg; <em>p</em> &lt; 0.001) in the intervention group compared with those in the controls. This hypertension DTx app also exhibits potential lifetime cost-effectiveness. Regarding insomnia management, SUSMED MedCBT-i supports physician-delivered cognitive behavioral therapy for insomnia. In a randomized controlled trial, Athens Insomnia Scale scores significantly improved in the intervention group compared with those in the controls (between-group difference, −3.4 point; <em>p</em> &lt; 0.001) at 8 weeks. These DTx apps represent a significant advancement in managing chronic conditions, offering scalable and accessible methods for delivering evidence-based interventions. They also address the challenges in implementing lifestyle modifications and behavioral therapies in traditional healthcare settings. As DTx become more integrated into routine clinical practice, ongoing research is crucial to evaluate their long-term efficacy, safety, and cost-effectiveness. The success of these initial DTx apps in Japan paves the way for more comprehensive digital health solutions, potentially improving individual patient outcomes and contributing to larger-scale public health improvements in managing chronic conditions.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"85 5","pages":"Pages 360-365"},"PeriodicalIF":2.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}